medigraphic.com
ISSN 1561-2988 (Print)

2023, Number 1

<< Back Next >>

Rev Cubana Farm 2023; 56 (1)

Validation of the modified Lowry to quantify the protein content of an allergy vaccine

Martínez MY, Mateo MM, Ramírez GW, García FA, Revilla FY, Labrada RA

Language: Spanish
References: 21
Page: 1-15
PDF size: 387.34 Kb.


ABSTRACT

Introduction: Prolinem BT is a second-generation vaccine candidate that uses as active ingredient allergens purified from Blomia tropicalis mite extract, which constitute the major allergens of that species.
Objective: Validation of the microplate modified Lowry as a technique to quantify the total protein content of the active ingredient of the PROLINEM-BT vaccine.
Methods: For the quantification of these purified proteins, the microplate modified Lowry technique was developed and validated. The parameters studied in the validation were specificity, linearity and parallelism, precision and accuracy.
Results: The method was specific in the quantification of total proteins. The curve ranges from 20 to 100 μg/mL and had a linear behavior (r = 0.99). The technique is precise based on the coefficients of variation obtained (all less than 5 %) and accurate since all values presented 100 % recovery.
Conclusions: It was demonstrated that the Lowry method modified to microplates is valid for the quantification of total proteins of the active ingredient of Prolinem BT.


REFERENCES

  1. Pascal D, Matucci A, Rossi O, Vidal C. The disease burden in patients with respiratory allergies induced by house dust mites: a year-long observational survey in three European countries. Clin. Transl. Allergy. 2020;10(27):1-12. DOI: 10.1186/s13601-020-00331-0

  2. Miller JD. The Role of Dust Mites in Allergy. Clinic Rev Allerg Immunol. 2019;57:312-29. DOI: 10.1007/s12016-018-8693-0

  3. Santos E, Asam C, Lackner P, Hofer H, Wallner M, Silva Pinheiro C, et al. Allergens of Blomia tropicalis: An Overview of Recombinant Molecules. Int Arch Allergy Immunol. 2017;172(4):203-14. DOI: 10.1159/000464325

  4. Labrada A. Desarrollo a ciclo completo de las primeras vacunas estandarizadas de alergenos de ácaros para la inmunoterapia del asma en Cuba. La Habana: Editorial Universitaria; 2012. DOI: 10.13140/RG.2.2.31180.26249

  5. Di Felice G, Colombo P. Nanoparticle–allergen complexes for allergen immunotherapy. Int J Nanomedicine. 2017;12:4493-4504. DOI: 10.2147/IJN.S134630

  6. Chang A, Ochoa R, Climent Y, Macías C, Rodríguez L, Valenzuela C, et al. A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial. The Lancet Regional Health - Americas. 2021;4:100079-090. DOI: 10.1016/j.lana.2021.100079

  7. Ramírez W, Bourg V, Torralba D, Facenda E, Tamargo B, González B, et al. Safety of a proteoliposome from Neisseria meningitides as adjuvant for a house dust mite allergy vaccine. J Immunotoxicol. 2017;14(1):152-59. DOI: 10.1080/1547691X.2017.1346007

  8. Jensen E, Roth F, Jordakieva G, Pali I. Allergens and adjuvants in Allergen Immunotherapy for immune activation, tolerance and resilience. J Allergy Clin Immunol Pract. 2021;9(5):1780-89. DOI: 10.1016/j.jaip.2020.12.008

  9. Mateo M, Ramírez W, Torralba D, Revilla Y, Cruz R, Espinosa BL, García A, et al. LIBRO DE RESÚMENES, Prolinem-BT, vacuna de segunda generación para la alergia a Blomia tropicalis. Revista VacciMonitor. 2022 [acceso 18/04/2022];61. Disponible en: https://vaccimonitor.finlay.edu.cu/index.php/vaccimonitor/article/view/313/512

  10. Samalea R, Torralba D, Martínez D, Ramírez W, Mateo M, Oliva Y, et al. Desarrollo de la formulación, escalado y estabilidad de la vacuna antialérgica de Dermatophagoides siboney adyuvada con gel de hidróxido de aluminio. Revista CENIC Ciencias Biológicas. 2019 [acceso 18/04/2022];49(2):1-14. Disponible en: https://revista.cnic.edu.cu/index.php/RevBiol/article/view/186

  11. European Pharmacopoeia. Monograph on allergen products. 2017 [acceso 18/04/2022]:1063. Disponible en: https://file.wuxuwang.com/yaopinbz/EP9/EP9.0_01__351.pdf

  12. CECMED. Requisitos para las solicitudes de inscripción en el registro de medicamentos de uso humano de productos alergénicos. CECMED: La Habana, 2002 [acceso 19/01/2022]. Disponible en: https://www.cecmed.cu/sites/default/files/adjuntos/Reglamentacion/Reg_30-02.pdf.

  13. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. Journal Biol Chem. 1951;193:265-75. PMID: 14907713

  14. Fryer HJ, Davis GE, Manthrope M, Varon S. Lowry protein assay using a automatic microtiter plate spectophotometer. Anal Biochem. 1986;153(2):262-6. DOI: 10.1016/0003-2697(86)90090-4

  15. Resolución No. 40 del 2014. Anexo No.1 de las Buenas Prácticas para Laboratorios de Control de Medicamentos. Validación de Métodos Analíticos. CECMED; 2014 [acceso 28/12/2021]:1-30. Disponible en: https://www.cecmed.cu/reglamentacion/aprobadas/resolucion-cecmed-40

  16. Zimmer J, Bonertz A, Vieths S. Quality requirements for allergen extracts and allergoids for allergen immunotherapy. Allergol Immunopathol. 2017;45(S1):4-11. DOI: 10.1016/j.aller.2017.09.002

  17. Bonertz RG, Hoefnagel M, Timon M, Slater J, Rabin R. Challenges in the implementation of EAACI guidelines on allergen immunotherapy: A global perspective on the regulation of allergen products. Allergy. 2018;73:64-76. DOI: 10.1111/all.13266

  18. Lehnigk U. Allergen immunotherapy in the European regulatory environment. Medical Writing. 2018 [acceso 28/12/2021];27(1):30-4 ISSN 2047-4814. Disponible en: https://journal.emwa.org/vaccines-and-immunotherapies/allergen-immunotherapy-in-the-european-regulatory-environment/article/3583/lehnigk_-allergen-immunotherapy-in-the-european-regulatory-environment.pdf.

  19. International scientific guideline: Guideline on allergen products: Production and quality issues. EMEA/CHMP/BWP. Adopted by the Therapeutic Goods Administration (TGA). 2007 [acceso 28/12/2021]. Disponible en: https://www.tga.gov.au/resources/resource/international-scientific-guidelines/international-scientific-guideline-guideline-allergen-products-production-and-quality-issues

  20. ICH guideline Q2(R2) Validation of analytical procedures. A Notice by the Food and Drug Administration. 2022 [acceso 28/12/2021]. Disponible en: https://www.federalregister.gov/documents/2022/08/29/2022-18516/q2r2-validation-of-analytical-procedures-and-q14-analytical-procedure-development-international.

  21. Yglesias A, Viera A, Suárez Y, Torres JR, Ochoa R. Validation of Modified Lowry for the Determination of Total Protein Concentration of Rhopalurus junceus Scorpion Venom. Biomed J Sci & Tech Res. 2020;28(3):21627-32. DOI: https://doi.org/10.26717/BJSTR.2020.28.004655




2020     |     www.medigraphic.com